Consideration of epigenetic inhibitors for novel therapeutic approaches
Our laboratory has been following a model for the combined inhibition of a genetic-to-epigenetic pathway to treat pancreatic cancer, as an important and provocative consideration for harnessing the capacity of cell cycle inhibitors in efforts to not only enhance the future use of epigenetic inhibitors, but also translate similar approaches to other genetic-to-epigenetic pathways to control cancer growth.
Please sign in or register for FREE to view this content
Register to EpigenomicsNet – the epigenetics and epigenomics network
EpigenomicsNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.